cyrilzakka/clinical-trials huggingface dataset:
Examining the Effect of Prolotherapy on Quality of Life and Painkiller Use in Patients With Knee Pain

92 patients with a diagnosis of primary knee pain of unknown cause followed at the family medicine outpatient clinic and who met our exclusion criteria were invited to the study. When creating patient list, the examination of patients, interviews with patients, as well as their medical records and examinations were used. Patients were divided into two groups: prolotherapy (n=46) and control group (n=46) by simple randomization method. However, when the study started, 32 people in the prolotherapy group and 33 people in the control group of these patients participated in the study. Prior to the research, detailed information was provided about the research in the experimental and control groups and signed consent was obtained from all participants that they volunteered to participate in the research. 5% dectrose was applied to the prolotherapy group by injection method to the pain area. In the control group, existing medical treatments were continued and no injection procedure was performed. Before the research, all participants were evaluated with Case Report Form, Visual Analog Scale (VAS) and Quality of Life Scale Short Form (SF-36). The cases in the experimental and control groups were re-evaluated with the VAS and SF-36 scales at the first month.


Eligibility Criteria:
Inclusion Criteria:

* patients who suffer from primary knee osteoarthritis

Exclusion Criteria:

* Inflammatory knee pain
* Cellulitis
* Septic arthritis
* Local abscess
* Bleeding disorders
* Patient on anticoagulant medication
* Patients allergic to dextrose
* Diabetes Mellitus
* breathing problems
* Electrolyte imbalance
* Kidney or liver disease
Lidocaine For Neuroprotection During Cardiac Surgery

The purpose of this study is to see if a drug called lidocaine prevents cognitive injury (a decline in mental abilities) after heart surgery. Lidocaine is currently FDA approved and is commonly used for treating some heart rhythm disorders and for regional anesthesia (blocking nerves). The investigators are enrolling subjects in this research project to see if lidocaine will reduce the high incidence of cognitive injury seen after heart surgery. As part of this study, the investigators will also evaluate the relationship between cognitive injury and genetic makeup and the chemical changes in the subjects blood during and after surgery.


Eligibility Criteria:
Inclusion Criteria:

1. CABG, CABG + Valve, or Valve surgery
2. Use of cardiopulmonary bypass

Exclusion Criteria:

1. Less than 50 years of age
2. History of diabetes
3. History of symptomatic cerebrovascular disease (e.g. prior stroke) with residual deficit
4. Alcoholism (\> 2 drinks/day)
5. History of psychiatric illness (any clinical diagnoses requiring therapy)
6. History of drug abuse (any illicit drug use in the past 3 months)
7. Hepatic insufficiency (liver function tests \> 1.5 times the upper limit of normal)
8. Severe pulmonary insufficiency (requiring home oxygen therapy)
9. Renal failure (baseline serum creatinine \> 2.0 mg/dl)
10. Pregnant women
11. Unable to read and thus unable to complete the cognitive testing
12. Score \< 24 on a baseline Mini Mental State examination (MMSE) or greater than or equal to 27 on the baseline Center for Epidemiological Studies Depression (CES-D) Scale -
A Correlation Study of Internal Jugular Vein Variability Under Deep Inhalation and Propofol-induced Hypotension

The correlation between internal jugular vein variability during deep inhalation and the decrease in blood pressure during propofol induction.

1. Ultrasound records at least one quiet breathing cycle and one deep inhalation cycle to calculate IJVV
2. Propofol was infused target-controlled at 4 μg/ml, and changes in arterial blood pressure within 3 minutes of propofol induction were observed.
3. Aim to conduct a prospective observational study to evaluate the correlation between internal jugular vein variability during deep inhalation and the decrease in blood pressure during propofol induction.

Eligibility Criteria:
Inclusion Criteria:

* age over 60 years
* American Society of Anesthesiology (ASA) status Ⅱ-Ⅲ
* Surgery with radial artery puncture
* Propofol induction

Exclusion Criteria:

* BMI≥30kg/m2
* People with short necks;
* Previous hypotension (systolic blood pressure \<90mmHg or mean arterial pressure \<65mmHg)
* Previous poorly controlled hypertension
* Cardiac insufficiency , EF value\<50%
* Upper limb deep vein thrombosis
* History of radiotherapy or neck surgery
* Inability to maintain a supine position for necessary measurements
* Mechanical ventilation status or inability to take deep breaths patients
* gastrointestinal surgery
* patients allergic to propofol.
Acute Effects of Inspiratory Muscle Training on Peripheral Muscle Metabolism and Autonomic Response in COPD Patients

The study will evaluate the acute effects of inspiratory muscle training (IMT) on peripheral muscle metabolism and autonomic response in patients with chronic obstructive pulmonary disease (COPD). This is a randomized, crossover study, with blinding of the evaluator and the researcher responsible for the statistical analysis. Participants will be divided into three groups at different times: TMI- strength (F), TMI to gain inspiratory muscle strength; IMT- resistance (R), IMT for improving inspiratory muscle resistance; and TMI sham. All participants randomized in the study will participate in the three groups, with a minimum interval of 48 hours between participation in each group. Randomization will determine the sequence of participation in the three groups for all participants.

For statistical analysis, an intention-to-treat approach will be used, and the groups will be compared using the Student's t test for continuous variables or the chi-square test for categorical variables. A split-plot ANOVA with repeated measures will be used for primary outcomes, and analysis of covariance will be conducted to identify differences between groups using baseline scores as covariates. Effect sizes and confidence intervals will be calculated using eta squared.

It is expected that IMT applied at different loads can promote effects on vascular function, peripheral muscle metabolism and the response of the autonomic nervous system in patients with COPD, which can greatly contribute to the understanding of the physiological effects of this therapy and support its prescription. as a therapeutic intervention in the rehabilitation of patients with pulmonary diseases.


Eligibility Criteria:
Inclusion Criteria:

* Patients with COPD according to the Global Initiative for COPD (GOLD, 2023);
* Aged 40 years or older and under 75 years;
* Providing both oral and written informed consent.

Exclusion Criteria:

* Inability to perform the IMT protocol and/or functional tests;
* Presence of psychiatric disorders or cognitive impairments, progressive neurological disorders, cancer, or chronic pain;
* Cognitive impairment or inability to understand commands.
* Patients who have experienced any health issue or had a COPD exacerbation in the previous month will also be excluded to ensure that the patient's symptoms are stable.
Neurocognitive Impairment and Psychiatric Comorbidities in HIV-1

To assess the prevalence and risk factors of neurocognitive impairment and psychiatric comorbidities in HIV infected patients who have undetectable viral load, have been on HAART for at least 1 year and have no history of CNS infection.

To understand how to prevent and treat HIV-associated neurocognitive impairment and psychiatric comorbidities in HIV-infected Thai individuals who don't have current AIDS related illness or current and prior central nervous system (CNS) infection, and have been well treated with HAART with undetectable HIV RNA.

Eligibility Criteria:
Inclusion Criteria:

* Signed informed consent
* Evidence of HIV infection (confirmed positive ELISA and documented history of measurable HIV RNA)
* Age \> 18 years old
* Plasma HIV RNA of \< 50 copies/ml within 3 months prior to screening
* Have been on only NNRTI-based HAART regimen for the entire duration and for at least1 year.

Exclusion Criteria:

* Current AIDS defining illnesses
* Current or history of previous CNS infection.
* Head injury with loss of consciousness greater than 1 hour
* Acute illness within 30 days prior to entry that, in the opinion of investigators, would prevent patients from completing the protocol required procedures.
* Known learning disability including dyslexia
Efficacy Of Eptifibatide Compared To Abciximab In Primary Percutaneous Coronary Intervention (PCI) For Acute ST Elevation Myocardial Infarction (STEMI)

Multinational, multicentre, randomised, prospective, open, parallel group study directly comparing two glycoprotein-IIb/IIIa inhibitors, abciximab and eptifibatide, added early to standard treatment before primary PCI of STEMI patients with respect to effect on sum-ST-resolution after 60 minutes post-procedure and other measures of myocardial reperfusion


Eligibility Criteria:
Inclusion Criteria:

* Women must be postmenopausal (i.e.12 months without menstrual period), or surgically sterile, i.e. women of child bearing potential are not allowed to be included into the study. In cases of doubt a pregnancy test should be performed. (NB -post menopausal women currently receiving hormone replacement are permissible)
* Acute myocardial infarction \< 12 h defined as:

  1. Angina or equivalent symptoms \> 20 min and
  2. ST elevation in 2 contiguous ECG leads (= 2 mm precordial lead, = 1 mm limb lead). This ECG recording serves as baseline ECG, i.e. ECG I.
* Planned primary percutaneous coronary intervention
* The subject has given written informed, dated consent to participate in the study

Exclusion Criteria:

* Subjects not able to give informed consent
* Left Bundle Branch Block
* Thrombolytic therapy within 24 hours before randomization
* Oral anticoagulation with International Normalized Ratio (INR) \> 2
* Known platelets \< 100.000/µl or known hemorrhagic diathesis
* Stroke or Transient Ischemic Attack (TIA) within the past 6 months or any permanent residual neurological defect
* Evidence of an active gastrointestinal or urogenital bleeding
* Major surgery within 6 weeks
* History of allergic reaction to abciximab or eptifibatide or any component used in the study (including contrast media)
* Known severe renal (creatinine clearance \<30ml/min) or hepatic insufficiency as well as Alanine transaminase (ALT)/aspartate transaminase (AST) elevations = 3xUpper limit normal (ULN); isolated AST-elevation is not considered an exclusion criteria from study participation
* Severe concomitant disease with life expectation \< 1 year
* Subject has participated in any study using an investigational drug or device within 30 days or within 5 half-lives of the investigational drug (whichever is longer) of entry into this study.
* Subjects who will be inaccessible due to geographic or social factors during treatment or follow-up
* In France, a subject is neither affiliated with nor a beneficiary of a social security category.
Therapeutic Effect of Repetitive Transcranial Magnetic Stimulaton on Tinnitus

The purpose of this study is to determine whether repetitive transcranial magnetic stimulation (rTMS) is effective in the treatment of tinnitus.


Eligibility Criteria:
Inclusion Criteria:

* Subjective tinnitus
* Age 18 years and older

Exclusion Criteria:

* Meniere, conductive hearing loss, objective tinnitus
* History of seizure disorder or epilepsy
* Clinically relevant psychiatric comorbidity
* Previous symptomatic stroke
* Surgically or traumatically implanted foreign bodies such as a pacemaker, an implanted medication pump, a metal plate in the skull, or metal inside the skull or eyes (other than dental appliances or fillings), intracardiac lines that may pose a physical hazard during magnetic stimulation
Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study

Several treatments have been used in during the Covid-19 pandemic of 2020. Using patients' registries from several hospitals in Paris, the investigators retrospectively analyzed associations between specific treatments, including but not limited to vaccines targeted against SARS-CoV-2, hydroxychloroquine, azithromycin, remdesivir, baricitinib, tocilizumab, sarilumab, lopinavir/ritonavir and oseltamivir; and clinical outcomes including, death and mechanical ventilation.

Several treatments have been used in during the Covid-19 pandemic of 2020. Using patients' registries from several hospitals in Paris, the investigators retrospectively analyzed associations between specific treatments, including but not limited to vaccines targeted against SARS-CoV-2, hydroxychloroquine, azithromycin, remdesivir, baricitinib, tocilizumab, sarilumab, lopinavir/ritonavir and oseltamivir; and clinical outcomes including, death and mechanical ventilation.

Other outcomes of interest include: acute kidney injury, encephalopathy, need for intensive care unit transfers.

Eligibility Criteria:
Inclusion Criteria:

* admitted for severe Covid-19 pneumonia (i.e. requiring O2-support more than 6L/min with SpO2\<96%)

Exclusion Criteria:

* patients who were previously in ICU
* patients already hospitalized prior to study start date
* patients in palliative care
* lack of consent
Cash Transfers for People Experiencing Homelessness

The primary goal of the study is to determine the impacts of a one-time unconditional cash transfer on the well-being of people experiencing homelessness.

The goal of this project is to examine the effect of cash-transfers for people experiencing homelessness in Metro Vancouver. In partnership with Foundations for Social Change, we will distribute a one-time unconditional cash transfer of $8,500 to each of the 200 participants, with 200 additional participants in a control group who will not receive the cash transfer. To evaluate the effect of the cash transfer, participants will complete surveys 1, 2, 3, 6, 9, and 12 months after the cash transfer, and we will track important life outcomes such as housing, employment, health, cognitive function, and well-being.

Eligibility Criteria:
Inclusion Criteria:

1. Participants must be homeless at the time of recruitment.
2. Participants must be between 18 and 65 years of age, inclusive.
3. Participants must be a Canadian citizen or permanent resident in Canada

Exclusion Criteria:

The following participants will be excluded:

1. Participants who report severe problematic substance use (score ≥ 6 on DAST).
2. Participants who report severe problematic alcohol use (score ≥ 20 on AUDIT).
3. Participants who report severe psychiatric symptoms (score above 2 on item 5 or above 4 on items 13 or 14 on CSI).
4. Participants who report problematic gambling behavior (score ≥ 8 on PGSI).
A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function

This Phase 1, open-label, single dose study is designed to evaluate the pharmacokinetics, safety and tolerability of a single 1.5 mg tivozanib dose in subjects with varying degrees of hepatic impairment and normal hepatic function.


Eligibility Criteria:
Inclusion Criteria:

* BMI between 18 to 38 kg/m2
* diagnosis of chronic or stable hepatic insufficiency, with a Child-Pugh classification scores of mild, moderate or severe.

Exclusion Criteria:

* Current or previous history of hepatic carcinoma, hepatorenal syndrome, portacaval shunt surgery, significant hepatic encephalopathy, severe ascites, or pleural effusion
* Currently undergoing dialysis
* Poor peripheral venous access
* Pregnancy or lactation
Quality Improvement - Monitoring Alarm Optimization Study

This project aims to reduce the frequency of duplicate, false and clinically insignificant alarms in hospital units, and subsequent alarm fatigue resulting from excessive alarm frequency. The investigators will implement evidence-based guidelines for alarm optimization according to patient-population specific parameters, and evaluate alarm frequency and staff perception of alarm fatigue at baseline and 60 days after implementation of this quality improvement initiative.


Eligibility Criteria:
Inclusion Criteria:

* Nursing staff at selected units at Duke University Hospital

Exclusion Criteria:

* NA
Urine Cytology and Utility in Bladder Recurrence

Review bladder cancer patients and form a database in regards to urine cytology.

In 2008 there was an estimated 68,810 new cases of bladder cancer, and 14,100 deaths. On the list of morbidity due to cancer, bladder cancer ranks number nine, yet is number one in dollars spent per cancer diagnosis and treatment.

Guidelines include cystoscopy and cytology/urine study every three months for the first 2 years and then every 6 months for the next 2 years, with the cycle being reset with every recurrence.

Urine cytology currently considered the gold standard for urine tests has many pros and cons. The points that keep it in use include: its high specificity, the ability to detect upper tract occurrence, and the ability to monitor the small population of those with bladder cancer whose disease becomes more aggressive. Opponents to cytology refer to the fact that is has low sensitivity that it is fairly subjective and that newer markers in comparison are improved.

There are multiple journal article which document the performance of cytology and the newer markers, the new markers versus cytology and then the performance of cytology in tandem with these new markers. The bottom line that is often overlooked is that cytology is expensive and each of the newer markers are at least as expensive as cytology. With the fact that a person who is diagnosed with non invasive bladder cancer can have up to 13 urine cytology's in 5 years without any recurrence we believe newer rational recommendations need to be made in regards to urine studies and bladder cancer follow up.

Eligibility Criteria:
Inclusion Criteria:

* Bladder cancer patients from Dr. Jay Hollander's private practice.

Exclusion Criteria:

* Patients with diagnosis of bladder cancer without initial cytology available.
* Patients who received outside nephrectomy or cystectomy without pathology available.
* Those who had recurrence without cytology results available.
* Those who were followed by Dr Hollander and another urologist in which records are missing for a significant number of follow ups.
The Beijing Childhood Eye Study

Axial myopia has emerged as the leading cause of irreversible vision loss in East Asia, driven by its progression to sight-threatening complications including myopic macular degeneration, retinal detachment, open-angle glaucoma, and other complications. In the current study, we aim to observe the natural course of the development , progression, and its associated factors in children

This is a prospective epidemiological cohort study, recruiting students in grades 1-3 in primary school for myopia. Through stratified cluster random sampling, among aii the primary schools in Dongcheng District, Beijing, schools were stratified into key and ordinary schools, with 2 schools randomly selected from each stratum.

A prospective study cohort comprising 3,667 subjects was established. All study subjects completed a standard questionnaire and underwent routine ophthalmic examinations. Follow-up assessments will be conducted regularly to monitor changes in refractive errors and fundus indicators. Informed consent, approved by the Ethics Committee of Beijing Tongren Hospital, was obtained from all participants.

Eligibility Criteria:
Inclusion Criteria: 1) Currently enrolled students in grades 1-3 of the selected primary schools, in good health, with normal ocular appearance. 2) No ocular diseases, no strabismus, ocular trauma, or history of intraocular surgery, with unaided visual acuity of 20/20 or better. 3) Parental and student consent to participate in the survey and signed informed consent form.

Exclusion Criteria: 1) Not currently enrolled in grades 1-3 of a primary school. 2) Students with pre-existing strabismus, other ocular diseases, or a history of ocular surgery at baseline, or those allergic to cycloplegic eyedrops. 3) Students unable to continue studying at their current school for more than three years from the baseline, including those who transfer to another school or withdraw from the study; 4) parental or student disagreement with participation in the survey.
Pharmacokinetics of Low Molecular Weight and Unfractionated Heparin in Pregnancy

To determine, through pharmacokinetic parameters, the ideal dosing protocol for dalteparin (a low molecular weight heparin) and unfractionated heparin for women desiring pregnancy who have evidence of an acquired (specifically, antiphospholipid syndrome) or inherited thrombophilia.

This study's specific objectives include:

1. Evaluating pharmacokinetic (concentration-time) and pharmacodynamic (concentration- effect) parameters for dalteparin and UFH prior to pregnancy, during the 1st, 2nd and 3rd trimesters and postpartum, using revised dosing protocols based on previous study.
2. Determining therapeutic response to the heparins, i.e. live birth rate and lack of maternal or fetal complications, in relation to drug exposure, based on AUC.
3. Documenting maternal and fetal complications during pregnancy for dalteparin and UFH, using the revised dosing protocols.

Eligibility Criteria:
Inclusion Criteria:

* Two or more consecutive, otherwise unexplained miscarriages under 10 weeks of gestation, or, an otherwise unexplained intrauterine fetal demise of at least 10 weeks of gestation, and,
* Persistently positive antiphospholipid antibodies, or, presence of Factor V Leiden, or, Prothrombin 20210A, or, antithrombin, protein S, or protein C deficiency, or, hyperhomocysteinemia associated with the methylenetetrahydrofolate reductase (MTHFR) polymorphism.

Exclusion Criteria:

* Inability or refusal to give written informed consent.
* Inability or refusal to self-administer heparin throughout pregnancy.
* Hemoglobin value below 9.5 g/dL
* Heparin use is contraindicated.
* Renal disease.
* Documented history of thrombosis.